NewEdge Wealth LLC Grows Stock Holdings in Collegium Pharmaceutical, Inc. $COLL

NewEdge Wealth LLC increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 59.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,893 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,529 shares during the period. NewEdge Wealth LLC’s holdings in Collegium Pharmaceutical were worth $1,286,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Group One Trading LLC acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd increased its stake in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Collegium Pharmaceutical during the fourth quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 318 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock opened at $35.20 on Monday. The business has a 50-day moving average of $34.65 and a 200-day moving average of $37.88. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The company has a market capitalization of $1.14 billion, a PE ratio of 17.25 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 1-year low of $29.19 and a 1-year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period in the previous year, the company earned $1.49 earnings per share. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on COLL shares. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Finally, Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $57.50.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.